| Literature DB >> 24853127 |
Bao-Sheng Zhou1, Guo-Yun Bu2, Mu Li3, Bin-Ge Chang4, Yi-Pin Zhou5.
Abstract
Stroke is currently the leading cause of functional impairments worldwide. Folate supplementation is inversely associated with risk of ischemic stroke. Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme involved in folate metabolism. The aim of this study is to examine whether genetic variants in MTHFR gene are associated with the risk of ischemic stroke and fasting total serum homocysteine (tHcy) level. We genotyped nine tag SNPs in the MTHFR gene in a case-control study, including 543 ischemic stroke cases and 655 healthy controls in China. We found that subjects with the rs1801133 TT genotype and rs1801131 CC genotype had significant increased risks of ischemic stroke (adjusted odds ratio (OR)=1.82, 95% confidence interval (CI): 1.27-2.61, p=0.004; adjusted OR=1.99, 95% CI: 1.12-3.56, p=0.01) compared with subjects with the major alleles. Haplotype analysis also found that carriers of the MTHFR CTTCGA haplotype (rs12121543-rs13306553-rs9651118-rs1801133-rs2274976-rs1801131) had a significant reduced risk of ischemic stroke (adjusted OR=0.53, 95% CI: 0.35-0.82) compared with those with the CTTTGA haplotype. Besides, the MTHFR rs1801133 and rs9651118 were significantly associated with serum levels of tHcy in healthy controls (p<0.0001 and p=0.02). These findings suggest that variants in the MTHFR gene may influence the risk of ischemic stroke and serum tHcy.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24853127 PMCID: PMC4057767 DOI: 10.3390/ijms15058931
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Selected characteristics of cases and controls.
| Characteristics | Cases ( | Controls ( | |
|---|---|---|---|
| Age (year) | 66 (61–70) | 66 (60–70) | 0.76 |
| Sex (Male/Female) | 346/197 | 402/253 | 0.42 |
| Smoking (Yes/No) | 224/319 | 215/440 | 0.003 |
| Diabetes (Yes/No) | 137/406 | 81/574 | <0.001 |
| Hypertension (Yes/No) | 293/250 | 222/433 | <0.001 |
| BMI (kg/m2) | 24.3 (22.9–25.8) | 24.3 (23.0–25.7) | 0.55 |
| Total cholesterol (mmol/L) | 4.70 (4.09–5.48) | 4.14 (3.60–5.04) | 0.82 |
| HDL-C (mmol/L) | 1.20 (1.09–1.51) | 1.24 (1.08–1.56) | 0.008 |
| LDL-C (mmol/L) | 2.82 (2.45–3.29) | 2.48 (2.16–3.03) | <0.001 |
| Heart rate (bmp) | 72 (67–76) | 74 (68–78) | <0.001 |
Odds ratios (ORs) and 95% confidence intervals (CIs) for ischemic stroke in relation to polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene.
| SNP | Genotypes | Cases, | Controls, | OR (95% CI) | OR (95% CI) | P trend |
|---|---|---|---|---|---|---|
| rs12121543 | CC | 362 (66.8) | 449 (68.7) | 1.00 | 1.00 | |
| CA | 159 (29.3) | 185 (28.3) | 1.04 (0.80–1.36) | 0.99 (0.75–1.30) | ||
| AA | 21 (3.9) | 20 (3.1) | 1.42 (0.75–2.71) | 1.45 (0.74–2.84) | 0.61 | |
| CA + AA | 180 (33.2) | 205 (31.4) | 1.08 (0.84–1.39) | 1.03 (0.79–1.34) | ||
| rs13306561 | TT | 432 (79.7) | 529 (80.9) | 1.00 | 1.00 | |
| TC | 106 (19.6) | 121 (18.5) | 1.03 (0.76–1.39) | 0.95 (0.69–1.29) | ||
| CC | 4 (0.7) | 4 (0.6) | 1.27 (0.30–5.37) | 1.36 (0.30–6.18) | 0.67 | |
| TC + CC | 110 (20.3) | 125 (19.1) | 1.03 (0.77–1.39) | 0.96 (0.70–1.30) | ||
| rs13306553 | TT | 435 (80.3) | 534 (81.7) | 1.00 | 1.00 | |
| TC | 105 (19.3) | 116 (17.6) | 1.06 (0.78–1.44) | 0.97 (0.70–1.33) | ||
| CC | 2 (0.4) | 4 (0.6) | 0.62 (0.11–3.60) | 0.71 (0.11–4.55) | 0.54 | |
| TC + CC | 107 (19.7) | 120 (18.3) | 1.05 (0.78–1.41) | 0.96 (0.70–1.31) | ||
| rs9651118 | TT | 230 (42.4) | 273 (41.7) | 1.00 | 1.00 | |
| TC | 233 (43.0) | 291 (44.5) | 0.93 (0.72–1.20) | 0.93 (0.71–1.21) | ||
| CC | 79 (14.6) | 90 (13.8) | 1.05 (0.73–1.51) | 1.00 (0.69–1.46) | 0.66 | |
| TC + CC | 312 (57.6) | 381 (58.3) | 0.96 (0.75–1.21) | 0.95 (0.74–1.21) | ||
| rs1801133 | CC | 160 (29.5) | 242 (37.0) | 1.00 | 1.00 | |
| CT | 270 (49.8) | 308 (47.1) | 1.34 (1.03–1.76) | 1.31 (0.99–1.73) | ||
| TT | 112 (20.7) | 104 (15.9) | 1.64 (1.16–2.31) | 1.82 (1.27–2.61) | 0.04 | |
| CT + TT | 382 (70.5) | 412 (63.0) | 1.42 (1.10–1.83) | 1.44 (1.10–1.87) | ||
| rs2274976 | GG | 433 (79.9) | 542 (82.9) | 1.00 | 1.00 | |
| GA | 104 (19.2) | 107 (16.4) | 1.17 (0.86–1.60) | 1.10 (0.80–1.52) | ||
| AA | 5 (0.9) | 5 (0.8) | 1.34 (0.37–4.82) | 1.50 (0.39–5.69) | 0.21 | |
| GA + AA | 109 (20.1) | 112 (17.1) | 1.18 (0.87–1.60) | 1.12 (0.81–1.53) | ||
| rs4846048 | AA | 424 (78.5) | 538 (82.3) | 1.00 | 1.00 | |
| AG | 108 (20.0) | 111 (17.0) | 1.23 (0.90–1.66) | 1.19 (0.87–1.64) | ||
| GG | 8 (1.5) | 5 (0.8) | 2.60 (0.81–8.38) | 2.82 (0.83–9.54) | 0.12 | |
| AG + GG | 116 (21.5) | 116 (17.7) | 1.28 (0.95–1.72) | 1.25 (0.92–1.70) | ||
| rs1801131 | AA | 333 (61.4) | 448 (68.5) | 1.00 | 1.00 | |
| AC | 174 (32.1) | 182 (27.8) | 1.27 (0.97–1.64) | 1.19 (0.91–1.57) | ||
| CC | 35 (6.5) | 24 (3.7) | 1.97 (1.13–3.45) | 1.99 (1.12–3.56) | 0.03 | |
| AC + CC | 209 (38.6) | 206 (31.5) | 1.35 (1.05–1.73) | 1.29 (0.99–1.66) | ||
| rs17037396 | CC | 418 (77.1) | 500 (76.3) | 1.00 | 1.00 | |
| CT | 112 (20.7) | 142 (21.7) | 0.95 (0.71–1.27) | 0.96 (0.71–1.30) | ||
| TT | 12 (2.2) | 13 (2.0) | 1.22 (0.54–2.79) | 1.13 (0.49–2.62) | 0.71 | |
| CT + TT | 124 (22.9) | 155 (23.7) | 0.97 (0.73–1.29) | 0.97 (0.73–1.31) |
Adjusted for age;
Adjusted for age, cigarette smoking, diabetes and hypertension.
Association of haplotypes in the MTHFR gene with risk of ischemic stroke.
| Haplotype | Cases, % | Controls, % | OR (95% CI) | OR (95% CI) |
|---|---|---|---|---|
| CTTTGA | 38.7 | 38.7 | 1.00 | 1.00 |
| CTCCGA | 33.6 | 35.7 | 0.96 (0.79–1.17) | 0.92 (0.76–1.12) |
| ATTCGC | 6.8 | 8.7 | 0.79 (0.56–1.12) | 0.76 (0.54–1.08) |
| ACTCAC | 7.5 | 7.7 | 0.94 (0.67–1.33) | 0.88 (0.62–1.24) |
| CTTCGA | 3.2 | 6.6 | 0.55 (0.36–0.84) | 0.53 (0.35–0.82) |
In the order rs12121543, rs13306553, rs9651118, rs1801133, rs2274976, rs1801131;
Adjusted for age;
Adjusted for age, cigarette smoking, diabetes and hypertension.
Association between MTHFR polymorphisms and serum tHcy levels in healthy control.
| SNP | M/m | tHcy (mmol/L) | |||
|---|---|---|---|---|---|
|
| |||||
| MM | Mm | mm | |||
| rs12121543 | C/A | 12.4 (10.1–14.6) | 12.1 (9.7–13.7) | 10.8 (8.5–13.4) | 0.26 |
| rs13306561 | T/C | 12.1 (10.0–14.4) | 12.3 (10.2–14.1) | 9.1 (8.1–11.8) | 0.45 |
| rs13306553 | T/C | 12.1 (10.0–14.4) | 12.4 (10.1–14.2) | 9.1 (8.0–11.8) | 0.45 |
| rs9651118 | T/C | 12.5 (9.8–14.9) | 12.0 (10.0–13.8) | 11.5 (9.5–14.1) | 0.02 |
| rs1801133 | C/T | 10.9 (9.2–12.8) | 12.8 (10.9–14.6) | 13.1 (10.0–16.8) | <0.0001 |
| rs2274976 | G/A | 12.1 (10.0–14.4) | 12.3 (10.0–13.9) | 9.8 (8.4–13.7) | 0.57 |
| rs4846048 | A/G | 12.3 (10.1–14.4) | 11.6 (9.4–13.6) | 11.1 (10.3–11.6) | 0.36 |
| rs1801131 | A/C | 12.4 (10.0–14.6) | 12.2 (10.0–13.8) | 10.4 (8.6–13.4) | 0.36 |
| rs17037396 | C/T | 12.2 (10.0–14.4) | 11.9 (9.9–14.4) | 11.7 (11.4–12.9) | 0.94 |
M indicates major alleles; m indicates minor alleles.